Life Science News

RSS

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Affymetrix unveils Axiom Genotyping Solution

Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects.

From Beckman Coulter Life Sciences - Automation and Genomics 15 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

SAIC-Frederick and Roche collaborate on technology advancements in sequencing cancer genes

National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation, and Roche Applied Science, a division of Roche Diagnostics Corporation, have signed a collaboration agreement to assess Roche’s advanced technologies to sequence the genomes of cancer research samples.

From Roche Sequencing and Life Science 29 Sep 2009

Thermo Fisher to showcase food safety solutions at AOAC 2009, Philadelphia

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it is featuring its industry-leading range of instrumentation, equipment, consumables and software used for food safety testing at the AOAC International annual meeting and exposition in Philadelphia from Sept. 11-17.

From Thermo Fisher Scientific Inc. 15 Sep 2009

Digital Pathology Association has another Gold Sponsor: Sunquest Information Systems

Sunquest Information Systems, Inc., a market leader in laboratory and diagnostic information systems, today announced that it is a Founding Gold Sponsor of the Digital Pathology Association (DPA), a non-profit organization committed to the advancement of digital pathology applications in healthcare. The goals of the DPA include supporting digital pathology education initiatives, defining best practices, influencing standards and interfaces, organizing an annual conference that addresses diverse needs within the industry, and more.

From Evident Corporation - Life Sciences 14 Sep 2009

PDR merges with Health Care Notification Network

The iconic Physicians' Desk Reference (PDR®) found in every physician's office, clinic and hospital is merging with the Health Care Notification Network (HCNN), the only network that delivers FDA-required drug Alerts to physicians and other prescribers online.

From Physicians' Desk Reference (PDR) 10 Sep 2009

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue.

From Evident Corporation - Life Sciences 9 Sep 2009

Thermo Fisher Scientific receives Ringier Technology Innovation Award

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has received a Ringier Technology Innovation Award for its role in helping Chinese laboratories quickly develop melamine detection capabilities following the discovery of melamine-tainted milk and infant formula in China. The award was presented by Ringier Trade Publishing, which publishes China's leading food industry magazine, Food Manufacturing Journal.

From Thermo Fisher Scientific Inc. 9 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

Affymetrix and Beckman Coulter forge alliance to provide optimized genomic research solutions

Affymetrix, Inc. (Nasdaq: AFFX) and Beckman Coulter, Inc. today announced that they have entered into an agreement to offer researchers co-developed products from the market leaders in microarrays and automated liquid handlers.

From Beckman Coulter Life Sciences - Automation and Genomics 27 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

Cytori Therapeutics Q2 2009 financial results

Total revenues were $8.5 million and $10.5 million for the three and six months ended June 30, 2009, respectively, compared to $1.4 million and $2.4 million for the same periods in 2008. As part of Cytori’s Olympus partnership, the Company recognized $7.3 million in development revenue in the second quarter of 2009, due mostly to the completion of enrollment in the cardiovascular disease clinical safety and feasibility studies.

From Evident Corporation - Life Sciences 10 Aug 2009

The navel shown to be a safe and effective single access route for extracting kidneys

Successful surgery that leaves no scars has become the main objective of the most daring and innovative surgeons.

From Evident Corporation - Life Sciences 12 Mar 2009

New tool for 'right first time' drug manufacture

A technology which provides high quality images of the crystallisation process marks the next step towards a 'right first time' approach to drug manufacture, according to engineers at the University of Leeds.

From Malvern Panalytical 23 Sep 2008

Appendix removed through a patient's vagina

On March 26, 2008, surgeons at UC San Diego Medical Center removed an inflamed appendix through a patient's vagina, a first in the United States.

From Evident Corporation - Life Sciences 31 Mar 2008

Thermo Fisher Scientific creates breakthrough gene-silencing tool

Thermo Fisher Scientific Inc. has developed a breakthrough gene-silencing tool that greatly simplifies RNA- interference (RNAi) technology and eliminates barriers associated with previous cellular delivery methods.

From Thermo Fisher Scientific Inc. 12 Mar 2008

New advances in miRNA

miRNA research is now one of the most interesting areas in the life science world, reports Genetic Engineering and Biotechnology News (GEN).

From Thermo Fisher Scientific Inc. 3 Mar 2008

Breakthrough innovation for high sensitivity TB and Malaria diagnostics

At this year's 39th World Forum for Medicine in Dusseldorf (MEDICA, November 14-17), Partec, a globally leading developer, manufacturer and provider of dedicated diagnostic solutions in the response to HIV/AIDS, Tuberculosis and Malaria is presenting a breakthrough innovation for high sensitivity TB and Malaria diagnostics in low- and middle-income countries.

15 Nov 2007